2 year prolonged survival rate on a cancer biotech is huge on Wall Street
Sentiment: Strong Buy
bought and holding
The 5 Winners and Losers From ASCO Presentations
By Chris Lange
May 18, 2015
Winner ( ONTY )
make money -
insiders selling millions of shares link
Apr 24, 2015 AISLING CAPITAL II LPBeneficial Owner (10% or more) 67,469 Indirect Sale at $106.10 - $108 per share. 7,223,0002
Apr 24, 2015 GOLDSTEIN DOV A MDDirector 67,469 Indirect Sale at $106.10 - $108 per share. 7,223,0002
Apr 23, 2015 AISLING CAPITAL II LPBeneficial Owner (10% or more) 150,000 Indirect Sale at $109.10 per share. 16,365,000
Apr 23, 2015 GOLDSTEIN DOV A MDDirector 150,000 Indirect Sale at $109.10 per share. 16,365,000
Mar 20, 2015 DOMAIN PARTERS VII L PBeneficial Owner (10% or more) 350,000 Direct Disposition (Non Open Market) N/Mar 19, 2015 ENRIGHT PATRICK GDirector 500,000 Indirect Sale at $110.01 - $116.05 per share. 56,515,0002
Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts
By Adam Feuerstein
05/13/15 - 05:00 PM EDT
The research abstracts went live on ASCO's website at 5 p.m. EDT today, which means health care investors are now busy downloading and reading to find investable, stock-moving nuggets of clinical data.
Luckily, I had early access to the ASCO abstracts under an embargo. What follows is a list and summary of abstracts likely to be of greatest interest to biotech investors.
what a joke
out for now.
Investor Business Daily
CyberArk's new customers include 40% of Fortune 100 companies as well as many of the world's majorbanks.CyberArk is one of the highest ranked stocks by Composite Rating in the highly ranked securitysoftware industry group.